CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Quoin Pharmaceuticals announced plans to initiate investigator-led clinical studies for its QRX009 topical rapamycin lotion in several rare skin diseases including Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. The company aims to submit an Investigational New Drug (IND) application to the FDA by Q3 2026 for an additional …